Marine Drugs | |
Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis | |
Arturo Soto-Matos2  Sergio Szyldergemajn2  Sonia Extremera2  Bernardo Miguel-Lillo2  Vicente Alfaro1  Cinthya Coronado2  Pilar Lardelli2  Elena Roy2  Claudia Silvia Corrado2  | |
[1] Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain; | |
关键词: plitidepsin; cardiac toxicity; single agent; chemotherapy; cancer; | |
DOI : 10.3390/md9061007 | |
来源: mdpi | |
【 摘 要 】
Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that occurred in clinical trials with the single-agent plitidepsin. Demographic, clinical and pharmacological variables were explored by univariate and multivariate logistic regression analysis. Forty-six of 578 treated patients (8.0%) had at least one CAE (11 patients (1.9%) with plitidepsin-related CAEs), none with fatal outcome as a direct consequence. The more frequent CAEs were rhythm abnormalities (
【 授权许可】
CC BY
© 2011 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190049361ZK.pdf | 329KB | download |